Conjunctival Stromal Tumor: Report of 2 New Cases and Review of the Literature. (May 2021)

• Record Type: Journal Article
• Authors: Lam, Jonathan; Ang, Andrea; Vermeulen, Tersia; Ardakani, Nima Mesbah
• Is Part Of: International journal of surgical pathology. Volume 29:Number 3(2021)
• Page Start: 337
• Page End: 342
• Publication Date: 2021-05
• Subjects: conjunctival stromal tumor -- myxoma -- Carney complex -- solitary fibrous tumor -- CD34; Pathology, Surgical -- Periodicals; 617.07
• DOI: 10.1177/1066896920945783
• Languages: English
• ISSNs: 1066-8969

Abstract

Conjunctival stromal tumor (COST) is an emerging entity with only a limited number of cases reported in the literature. In this report, we describe 2 additional cases, review the accumulative clinical and histopathological features and expand on the immunophenotypic property of this entity. COST appears to have a sporadic presentation, affecting both sexes and patients of variable ethnicity and age group and predominantly occurring on the bulbar conjunctiva as a slow-growing asymptomatic or slightly tender mass-like lesion. Histopathologically, COST is characterized by singly dispersed spindle to round cells, often with some degree of degenerative nuclear atypia, within a myxomatous to collagenous stroma. Lesional cells are characteristically positive for CD34 and vimentin, negative for S100, SOX10 and STAT6 and show a normal pattern of staining with RB1 by immunohistochemistry. The reported cases to date have shown an indolent biological behavior, reliably treated by a complete surgical excision.